960 - Clinical impact of follow-up blood cultures in gram-negative bloodstream infections: A validation cohort

Thursday, October 12, 2023

1:45 PM – 2:00 PM US ET

Location: 104 ABC

Presenting Author(s)

Joshua T. Thaden, MD, PhD (he/him/his)

Assistant Professor
Duke University School of Medicine
Durham, NC, United States

Slides

Co-Author(s)

FR

Felicia Ruffin, MSN

Research Program Leader
Duke University Medical Center
Durham, North Carolina, United States
Joshua B. Parsons, MD, PhD

Fellow
Duke University Medical Center
Durham, North Carolina, United States
Vance G. Fowler, MD, MHS

Professor of Medicine
Duke University Medical Center
Durham, NC, United States
Stacey Maskarinec, MD, PHD

Assistant Professor
Duke University Medical Center
Durham, NC, United States

Disclosure(s):

Vance G. Fowler, MD, MHS: Amphliphi Biosciences, Integrated Biotherapeutics; C3J, Armata, Valanbio; Akagera, Aridis, Roche, Astra Zeneca: Advisor/Consultant (); Genentech, Regeneron, Deep Blue, Basilea, Janssen;: Grant/Research Support (); Infectious Diseases Society of America: Honoraria (); MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius;: Grant/Research Support (); Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny,: Advisor/Consultant (); Sepsis diagnostic: Patent pending (); UpToDate: Royalties (); Valanbio and ArcBio: Stock Options ()